Peerview Clinical Pharmacology Cme/cne/cpe Audio Podcast

Go online to PeerView.com/HCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immune checkpoint inhibitors (ICIs) changed the standards of care in the treatment of advanced solid tumors and are now rapidly transitioning into early-stage, curative-intent settings. New regulatory approvals have been recently granted for several ICIs as neoadjuvant and adjuvant treatments for different cancers, and many more studies are under way. This shift is truly needed, as outcomes had plateaued in resectable cancers. To overcome the challenges of conducting ICI clinical trials in early-stage cancers and facilitate more rapid progress, the need for new surrogate measures of efficacy has been widely recognized. Pathologic response assessment of resection specimens after neoadjuvant therapy has emerged as one such new tool, and there is accumulating evidence supporting its relevance and advantages. However, some unanswered questions remain, and there has been a lack o

Go online to PeerView.com/FSQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in asthma discusses the role of airway hyper-responsiveness in severe uncontrolled asthma. Upon completion of this activity, participants should be better able to: Compare the pathophysiology of airway inflammation with airway hyper-responsiveness (AHR) and their clinical manifestations in patients with severe asthma, Apply insights with regard to the role of AHR, as well as recent clinical evidence concerning the efficacy of biologic agents in addressing AHR, to the management of patients with severe asthma.

Go online to PeerView.com/JWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in multiple sclerosis discusses the use of anti-CD20 monoclonal antibodies in the treatment of relapsing MS. Upon completion of this activity, participants should be better able to: Describe the role of B cells in the pathogenesis of relapsing multiple sclerosis (MS), Assess the mechanisms of action, safety, and efficacy of anti-CD20 monoclonal antibodies used to treat relapsing forms of MS, Apply best practices and clinical evidence when using B cell–depleting therapies to optimize outcomes for patients with relapsing MS, Implement treatment plans designed to maximize COVID-19 vaccination efficacy in patients being treated for MS with anti-CD20 medications.

Go online to PeerView.com/JYU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating, progressive neurodegenerative disorder affecting 10% of people over age 65 and increasing in global prevalence. Recent advances in disease-modifying therapies have opened the door to the possibility of treatment approaches that can slow or prevent disease progression and improve patient outcomes. Now, with several anti–amyloid beta (Aβ) monoclonal antibodies in late-stage development, there is hope for families, clinicians, and researchers. The greatest likelihood of treatment success lies in timely diagnosis and early intervention. In this activity, based on a live symposium held at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases in Barcelona, Spain, an international panel of experts will discuss the importance of early recognition and diagnosis of AD and present the latest evidence on validated and emer

Go online to PeerView.com/JNH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert nephrologist examines the pathophysiology of chronic kidney disease (CKD) and the effects of mineralocorticoid receptor overactivation in patients with type 2 diabetes (T2D) to offer practical strategies for identifying which patients with CKD and T2D may benefit from treatment with nonsteroidal MRAs. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of CKD progression and the effects of mineralocorticoid receptor overactivation in patients with T2D, Compare the mechanism of action, potency, selectivity, and physiological distribution of steroidal and nonsteroidal MRAs, Identify patients with CKD and T2D that may derive specific benefit from treatment with nonsteroidal MRAs.

Go online to PeerView.com/TJZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in dermatology discuss strategies to optimize patient outcomes in atopic dermatitis and alopecia areata. Upon completion of this activity, participants should be better able to: Appropriately diagnose atopic dermatitis (AD) and alopecia areata (AA) and assess severity to determine the best treatment strategy in individual patients, recognizing wide variation in clinical presentation among different ethnicities, Describe current and emerging treatments for AD and AA in the context of mechanism of action, efficacy and safety profile, dosage and administration, and other factors relevant to clinical use, Utilize available resources to identify and overcome racial and ethnic health disparities in the management of AD and AA and ultimately improve health outcomes in under-represented populations.

Go online to PeerView.com/KCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapy in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 monoclonal antibodies is swiftly expanding from metastatic to early-stage, curative-intent settings in an increasing number of solid tumors. Furthermore, it’s on the cusp of further explosive growth as other novel agents, including inhibitors of new checkpoints such as LAG-3 and TIGIT, are starting to emerge. Pathologists and oncologists play a crucial role in identifying patients who would benefit the most from the broadening arsenal of immunotherapies and assessing response to these therapies. While there are substantial gaps in biomarker testing, pathologic response assessment, and the use of immunotherapies in current practice, things will only become more complicated. This PeerView Live educational activity, based on a recent symposium, will help you refine your current best practices and prepare you

Go online to PeerView.com/ABJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses best practices for improving screening and treatment of HCV infection in the primary care setting. Upon completion of this activity, participants should be better able to: Apply evidence-based guidelines for screening and evaluating patients for HCV infection in the primary care setting, Implement effective follow-up and counseling for patients upon a confirmed diagnosis of HCV infection, Differentiate currently available medications to treat HCV infection based on safety, efficacy, and recommended usage, Integrate direct-acting antiviral agents into individualized treatment plans for patients with HCV infection in accordance with current guidelines and expert recommendations, Employ a multidisciplinary team-based approach for treating HCV infection, distinguishing among patients who can be managed in the primary care setting versus those re

Go online to PeerView.com/DTN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intensely pruritic, hyperkeratotic nodules symmetrically distributed on the trunk and extremities. PN is defined by intense pruritus lasting ≥6 weeks, history of repeated scratching, and subsequent development of pruritic, elevated, firm, and nodular skin lesions, in a vicious itch–scratch cycle. The intense itch associated with PN leads to sleep disturbances and reduced social participation and work productivity, resulting in a drastically reduced quality of life and psychosocial disturbances. Unfortunately, these issues experienced among patients with PN are further compounded by the lack of effective treatment options. In this activity, based on a recent live educational symposium, a panel of experts addresses real-world questions and dilemmas faced by providers and the PN patients for whom they ca

Go online to PeerView.com/MRW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in asthma discusses the role of the airway epithelium in severe asthma treatment. Upon completion of this activity, participants should be better able to: Apply the latest pathophysiologic insights into the role of epithelial alarmins in the development of inflammation and structural changes in the airways to the treatment of patients with severe asthma, Discuss the clinical implications of biologic treatment that is not limited by phenotype or biomarker for patients with severe asthma whose disease remains uncontrolled despite standard treatment, Identify patients with severe asthma who may be eligible for treatment with novel biologic therapies that target epithelial alarmins.

Go online to PeerView.com/WFC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the last two decades, there have been very limited advancements in the treatment of HR+, HER2- early breast cancer, and a particularly marked unmet need has existed for patients at the highest risk of recurrence. Fortunately, there is new hope of improved outcomes for these patients following the recent FDA approval of the first CDK4 and 6 inhibitor for the adjuvant treatment of patients with HR+, HER2-, node+ early breast cancer at high risk of recurrence and a Ki-67 score ≥20%. Shortly thereafter, guideline updates were released that recommended adjuvant CDK4 and 6 inhibitor therapy combined with endocrine therapy to a broader population of patients at high risk of recurrence. The emergence of this new therapeutic option along with varied indications and recommendations has resulted in much uncertainty about which patients should and should not receive adjuvant CDK4 and 6 i

Go online to PeerView.com/HWY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic spontaneous urticaria (CSU) is defined by the presence of recurrent urticaria, angioedema, or both, for a period of 6 weeks or longer. There are several theories regarding the pathogenesis of CSU, none of which have been conclusively established. CSU is a self-limited disorder in most patients, with an average duration of disease of 2 to 5 years; although active CSU significantly impairs quality of life. Second-generation H1 antihistamines (sgAHs) in standard dose are effective in less than 50% of CSU patients. Increasing the dose of sgAHs improves treatment responses; however, every third to fourth patient will still remain symptomatic. Omalizumab, an anti-IgE monoclonal antibody, may also be used for effective treatment, as well as cyclosporine. The current guideline-recommended treatment algorithm, though useful, is not perfect. The treatment of patients with CSU shou

Go online to PeerView.com/KMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Screening and diagnosing atrial fibrillation (AF) is vital to implementing guideline-recommended treatment to reduce the risk of stroke. In this activity, an expert panel of pharmacists and a cardiologist discuss risk factors for AF, evidence-based strategies for screening and managing asymptomatic and symptomatic AF, and how multidisciplinary and interdisciplinary approaches to care increase screening and improve patient outcomes. Upon completion of this activity, participants should be better able to: Identify ways that pharmacists can work collaboratively with other clinical colleagues to bridge the gap between patients and healthcare team professionals to improve AF screening, diagnosis, and treatment, Screen individuals who are at risk for stroke due to undiagnosed AF and refer them for further evaluation and treatment, as appropriate, Collaborate with clinical colleagues t

Go online to PeerView.com/JBW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) comprise a critical component of the treatment arsenal for advanced/metastatic non–small cell lung cancer (NSCLC), with numerous single-agent and combination options approved for use in the first-line setting. Despite the availability of a broad array of immunotherapy options, not all patients benefit from or have access to these agents, especially those in underserved populations and communities. Innovative solutions are needed to help address some of the challenges and improve access to level the playing field for more patients with advanced/metastatic NSCLC. In this educational activity based on a recent web broadcast, experts provide useful clinical updates and multifaceted practical guidance for navigating the multitude of immunotherapy options for newly diagnosed patients with advanced/metastatic NSCLC. Upon completion of this activity,

Go online to PeerView.com/MZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent advances in multiple myeloma (MM) management present a rare opportunity for clinicians, who now have a variety of options to choose from when optimizing patient care. From this starting point, hematology-oncology professionals (including those practicing in community settings) and oncology nurses can leverage the potency of novel therapeutics, including platforms based on CD38 antibodies and novel BCMA-directed therapies, across the spectrum of disease. In this unique program, an interprofessional panel, featuring an academic and community hematologist-oncologist and a nurse professional, will use a series of case-based conversations to demonstrate exactly how to support the MM patient's therapeutic odyssey with innovative therapeutics—and deliver high-quality, collaborative patient care. Upon completion of this activity, participants should be better able to: Apply curre

Go online to PeerView.com/TZT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is often a necessary treatment for people with diabetes. Yet, knowing when to properly initiate and titrate insulin therapy in people with type 1 and type 2 diabetes is unfamiliar to many clinicians. In this activity, an expert discusses current guidance for incorporating individual preferences in insulin therapy in a variety of treatment regimens, models effective communication strategies in telehealth visits, and offers approaches to overcome common barriers to therapeutic inertia and engage patients to improve time in range and reduce postprandial glucose excursions. Upon completion of this activity, participants should be better able to: Incorporate newer options in mealtime insulin and the latest advances in technology to overcome barriers to insulin initiation, simplify insulin delivery and dosing, improve postprandial glucose (PPG) levels and time in range (TIR),

Go online to PeerView.com/PYK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting, a novel transcription inhibitor has expanded very limited options in the second-line setting, and many ongoing trials and innovative approaches are anticipated to further escalate progress in this challenging subtype of lung cancer. These developments have also provided new hope to patients with SCLC, which makes it important to ensure that all patients have access to these therapies and have the opportunity to benefit from them, as well as being encouraged to consider clinical trial participation. This activity focuses

Go online to PeerView.com/VHX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Poly (ADP-ribose) polymerase (PARP) inhibition is now the standard of care for metastatic breast cancer harboring a germline BRCA1 or BRCA2 mutation, and studies continue to investigate PARP inhibitors as monotherapies or in rational combinations. Most recently, exciting results have revealed a potential role for PARP inhibitor therapy in earlier disease settings where there is a possibility for cure, heralding a new era of targeted therapy for patients with breast cancer. In order to maximize the benefits of these advances, it is crucial for the multidisciplinary breast cancer care team to keep current with the latest data and expert recommendations to effectively integrate PARP inhibitor therapy into clinical practice, as well as genetic counseling and biomarker testing to refine individualized therapy selection. This PeerView educational activity, based on a recent live event

Go online to PeerView.com/YDT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. It is estimated that there are about 1 million adults in the United States who identify as transgender, and this number may be higher depending on the surveys used, the questions asked, and the diversity of subcultures within the transgender community. Although being transgender is not in itself a medical condition, transgender individuals have unique healthcare needs and face barriers to screening and preventive care, particularly with cancer screening. Consequently, these patients may receive lower quality medical care than the general population as a result of stigma, discrimination, and providers’ lack of knowledge about gender identity. Additionally, transgender patients may only seek medical care as part of gender affirmation and avoid primary care health concerns, including screenings. This activity, based on a recent live web broadcast, will focus on improving cancer pre

Go online to PeerView.com/KWF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in oncology discusses the role of immune checkpoint inhibitors in the care of patients with recurrent and advanced endometrial cancer. Upon completion of this activity, participants should be better able to: Implement appropriate strategies for biomarker testing and integration of novel immunotherapy options into personalized management plans for patients with recurrent or advanced endometrial cancer, in alignment with the latest clinical evidence, approved indications, and guideline recommendations, Employ proactive, collaborative strategies to mitigate and manage immune-related adverse events in patients receiving immune-based therapies for recurrent and advanced endometrial cancers, Apply multidisciplinary, interprofessional, and patient-centric practices and tools that can realistically serve to mitigate disparities in healthcare service delivery